Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs
Ulcerative colitis is the lead indication for Odyssey Therapeutics’ internally found lead drug candidate. With the IPO proceeds, Odyssey plans ...
Ulcerative colitis is the lead indication for Odyssey Therapeutics’ internally found lead drug candidate. With the IPO proceeds, Odyssey plans ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.